BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 15289848)

  • 21. High concordance of gene methylation in post-digital rectal examination and post-biopsy urine samples for prostate cancer detection.
    Rogers CG; Gonzalgo ML; Yan G; Bastian PJ; Chan DY; Nelson WG; Pavlovich CP
    J Urol; 2006 Nov; 176(5):2280-4. PubMed ID: 17070312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aberrant promoter methylation of laminin-5-encoding genes in prostate cancers and its relationship to clinicopathological features.
    Sathyanarayana UG; Padar A; Suzuki M; Maruyama R; Shigematsu H; Hsieh JT; Frenkel EP; Gazdar AF
    Clin Cancer Res; 2003 Dec; 9(17):6395-400. PubMed ID: 14695140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens.
    Gonzalgo ML; Pavlovich CP; Lee SM; Nelson WG
    Clin Cancer Res; 2003 Jul; 9(7):2673-7. PubMed ID: 12855646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A quantitative promoter methylation profile of prostate cancer.
    Jerónimo C; Henrique R; Hoque MO; Mambo E; Ribeiro FR; Varzim G; Oliveira J; Teixeira MR; Lopes C; Sidransky D
    Clin Cancer Res; 2004 Dec; 10(24):8472-8. PubMed ID: 15623627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequent hypermethylation of the RASSF1A gene in prostate cancer.
    Liu L; Yoon JH; Dammann R; Pfeifer GP
    Oncogene; 2002 Oct; 21(44):6835-40. PubMed ID: 12360410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypermethylation of the CpG islands in the promoter region of the GSTP1 gene in prostate cancer: a useful diagnostic and prognostic marker?
    Bernardini S; Miano R; Iori R; Finazzi-Agrò E; Palmieri G; Ballerini S; Angeloni C; Orlandi A; Bellincampi L; Cortese C; Federici G
    Clin Chim Acta; 2004 Dec; 350(1-2):181-8. PubMed ID: 15530476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Altered methylation of multiple genes in carcinogenesis of the prostate.
    Yamanaka M; Watanabe M; Yamada Y; Takagi A; Murata T; Takahashi H; Suzuki H; Ito H; Tsukino H; Katoh T; Sugimura Y; Shiraishi T
    Int J Cancer; 2003 Sep; 106(3):382-7. PubMed ID: 12845678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer.
    Ellinger J; Bastian PJ; Jurgan T; Biermann K; Kahl P; Heukamp LC; Wernert N; Müller SC; von Ruecker A
    Urology; 2008 Jan; 71(1):161-7. PubMed ID: 18242387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methylation of the ASC gene promoter is associated with aggressive prostate cancer.
    Collard RL; Harya NS; Monzon FA; Maier CE; O'Keefe DS
    Prostate; 2006 May; 66(7):687-95. PubMed ID: 16425203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients.
    Richiardi L; Fiano V; Vizzini L; De Marco L; Delsedime L; Akre O; Tos AG; Merletti F
    J Clin Oncol; 2009 Jul; 27(19):3161-8. PubMed ID: 19470943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer.
    Millar DS; Ow KK; Paul CL; Russell PJ; Molloy PL; Clark SJ
    Oncogene; 1999 Feb; 18(6):1313-24. PubMed ID: 10022813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Soy phytoestrogens modify DNA methylation of GSTP1, RASSF1A, EPH2 and BRCA1 promoter in prostate cancer cells.
    Vardi A; Bosviel R; Rabiau N; Adjakly M; Satih S; Dechelotte P; Boiteux JP; Fontana L; Bignon YJ; Guy L; Bernard-Gallon DJ
    In Vivo; 2010; 24(4):393-400. PubMed ID: 20668305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polymorphisms in the methylenetetrahydrofolate reductase gene and prostate cancer risk.
    Singal R; Ferdinand L; Das PM; Reis IM; Schlesselman JJ
    Int J Oncol; 2004 Nov; 25(5):1465-71. PubMed ID: 15492840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy.
    Bastian PJ; Palapattu GS; Lin X; Yegnasubramanian S; Mangold LA; Trock B; Eisenberger MA; Partin AW; Nelson WG
    Clin Cancer Res; 2005 Jun; 11(11):4037-43. PubMed ID: 15930338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation.
    Cairns P; Esteller M; Herman JG; Schoenberg M; Jeronimo C; Sanchez-Cespedes M; Chow NH; Grasso M; Wu L; Westra WB; Sidransky D
    Clin Cancer Res; 2001 Sep; 7(9):2727-30. PubMed ID: 11555585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy.
    Bastian PJ; Ellinger J; Heukamp LC; Kahl P; Müller SC; von Rücker A
    Eur Urol; 2007 Mar; 51(3):665-74; discussion 674. PubMed ID: 16956712
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects.
    Hoque MO; Topaloglu O; Begum S; Henrique R; Rosenbaum E; Van Criekinge W; Westra WH; Sidransky D
    J Clin Oncol; 2005 Sep; 23(27):6569-75. PubMed ID: 16170165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer.
    Fiolka R; Zubor P; Janusicova V; Visnovsky J; Mendelova A; Kajo K; Lasabova Z; Plank L; Danko J
    Oncol Rep; 2013 Dec; 30(6):2878-86. PubMed ID: 24068440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma.
    Maruyama R; Sugio K; Yoshino I; Maehara Y; Gazdar AF
    Cancer; 2004 Apr; 100(7):1472-7. PubMed ID: 15042681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.